<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2005-06-13" updated="2020-01-02">
  <drugbank-id primary="true">DB02313</drugbank-id>
  <drugbank-id>EXPT00453</drugbank-id>
  <name>Ethyl (4R)-4-{[(2R,5S)-2-(4-fluorobenzyl)-6-methyl-5-{[(5-methyl-1,2-oxazol-3-yl)carbonyl]amino}-4-oxoheptanoyl]amino}-5-[(3S)-2-oxo-3-pyrrolidinyl]pentanoate</name>
  <description/>
  <cas-number/>
  <unii/>
  <average-mass>600.688</average-mass>
  <monoisotopic-mass>600.295927839</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>experimental</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication/>
  <pharmacodynamics/>
  <mechanism-of-action/>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <salts/>
  <synonyms/>
  <products/>
  <international-brands/>
  <mixtures/>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories/>
  <affected-organisms/>
  <dosages/>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries>
    <pdb-entry>1cqq</pdb-entry>
    <pdb-entry>3qzq</pdb-entry>
    <pdb-entry>3qzr</pdb-entry>
    <pdb-entry>3r0f</pdb-entry>
    <pdb-entry>3ruo</pdb-entry>
    <pdb-entry>3sji</pdb-entry>
    <pdb-entry>3sjo</pdb-entry>
    <pdb-entry>4ght</pdb-entry>
    <pdb-entry>5hxf</pdb-entry>
    <pdb-entry>5wq2</pdb-entry>
  </pdb-entries>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>2.59</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-4.2</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>4.00e-02 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>2.82</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>ethyl (4R)-4-[(2S,5S)-2-[(4-fluorophenyl)methyl]-6-methyl-5-[(5-methyl-1,2-oxazol-3-yl)formamido]-4-oxoheptanamido]-5-[(3S)-2-oxopyrrolidin-3-yl]pentanoate</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>(2S)-2-{[(1S)-1-{[(1S)-1-carbamoyl-2-carboxyethyl]carbamoyl}-2-phenylethyl]amino}-4-phenylbutanoic acid</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>600.688</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>600.295927839</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>[H]N([C@H](CCC(=O)OCC)C[C@@H]1CCN([H])C1=O)C(=O)[C@H](CC(=O)[C@@H](N([H])C(=O)C1=NOC(C)=C1)C(C)C)CC1=CC=C(F)C=C1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C31H41FN4O7</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C31H41FN4O7/c1-5-42-27(38)11-10-24(16-21-12-13-33-29(21)39)34-30(40)22(15-20-6-8-23(32)9-7-20)17-26(37)28(18(2)3)35-31(41)25-14-19(4)43-36-25/h6-9,14,18,21-22,24,28H,5,10-13,15-17H2,1-4H3,(H,33,39)(H,34,40)(H,35,41)/t21-,22-,24+,28-/m0/s1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>LMIUALQNZXJHOG-ROJPAJKQSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>156.7</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>156.3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>62.27</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>17</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>6</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>12.5</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>-0.56</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>6323208</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46505563</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PDB</resource>
      <identifier>AG7</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0001494</id>
      <name>Genome polyprotein</name>
      <organism>HRV-2</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A1713</ref-id>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <ref-id>A1715</ref-id>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P04936" source="Swiss-Prot">
        <name>Genome polyprotein</name>
        <general-function>Structural molecule activity</general-function>
        <specific-function>Capsid protein VP1: Forms an icosahedral capsid of pseudo T=3 symmetry with capsid proteins VP2 and VP3. The capsid is 300 Angstroms in diameter, composed of 60 copies of each capsid protein and enclosing the viral positive strand RNA genome. Capsid protein VP1 mainly forms the vertices of the capsid. Capsid protein VP1 interacts with host VLDLR to provide virion attachment to target host cells. This attachment induces virion internalization. Tyrosine kinases are probably involved in the entry process. After binding to its receptor, the capsid undergoes conformational changes. Capsid protein VP1 N-terminus (that contains an amphipathic alpha-helix) and capsid protein VP4 are externalized. Together, they shape a pore in the host membrane through which viral genome is translocated to host cell cytoplasm. After genome has been released, the channel shrinks (By similarity).Capsid protein VP2: Forms an icosahedral capsid of pseudo T=3 symmetry with capsid proteins VP2 and VP3. The capsid is 300 Angstroms in diameter, composed of 60 copies of each capsid protein and enclosing the viral positive strand RNA genome (By similarity).Capsid protein VP3: Forms an icosahedral capsid of pseudo T=3 symmetry with capsid proteins VP2 and VP3. The capsid is 300 Angstroms in diameter, composed of 60 copies of each capsid protein and enclosing the viral positive strand RNA genome (By similarity).Capsid protein VP4: Lies on the inner surface of the capsid shell. After binding to the host receptor, the capsid undergoes conformational changes. Capsid protein VP4 is released, Capsid protein VP1 N-terminus is externalized, and together, they shape a pore in the host membrane through which the viral genome is translocated into the host cell cytoplasm. After genome has been released, the channel shrinks (By similarity).Capsid protein VP0: Component of immature procapsids, which is cleaved into capsid proteins VP4 and VP2 after maturation. Allows the capsid to remain inactive before the maturation step (By similarity).Protein 2A: Cysteine protease that cleaves viral polyprotein and specific host proteins. It is responsible for the cleavage between the P1 and P2 regions, first cleavage occurring in the polyprotein. Cleaves also the host translation initiation factor EIF4G1, in order to shut down the capped cellular mRNA translation. Inhibits the host nucleus-cytoplasm protein and RNA trafficking by cleaving host members of the nuclear pores (By similarity).Protein 2B: Plays an essential role in the virus replication cycle by acting as a viroporin. Creates a pore in the host reticulum endoplasmic and as a consequence releases Ca2+ in the cytoplasm of infected cell. In turn, high levels of cyctoplasmic calcium may trigger membrane trafficking and transport of viral ER-associated proteins to viroplasms, sites of viral genome replication (By similarity).Protein 2C: Induces and associates with structural rearrangements of intracellular membranes. Displays RNA-binding, nucleotide binding and NTPase activities. May play a role in virion morphogenesis and viral RNA encapsidation by interacting with the capsid protein VP3 (By similarity).Protein 3AB: Localizes the viral replication complex to the surface of membranous vesicles. Together with protein 3CD binds the Cis-Active RNA Element (CRE) which is involved in RNA synthesis initiation. Acts as a cofactor to stimulate the activity of 3D polymerase, maybe through a nucleid acid chaperone activity (By similarity).Protein 3A: Localizes the viral replication complex to the surface of membranous vesicles. It inhibits host cell endoplasmic reticulum-to-Golgi apparatus transport and causes the dissassembly of the Golgi complex, possibly through GBF1 interaction. This would result in depletion of MHC, trail receptors and IFN receptors at the host cell surface (By similarity).Viral protein genome-linked: acts as a primer for viral RNA replication and remains covalently bound to viral genomic RNA. VPg is uridylylated prior to priming replication into VPg-pUpU. The oriI viral genomic sequence may act as a template for this. The VPg-pUpU is then used as primer on the genomic RNA poly(A) by the RNA-dependent RNA polymerase to replicate the viral genome. VPg may be removed in the cytoplasm by an unknown enzyme termed "unlinkase". VPg is not cleaved off virion genomes because replicated genomic RNA are encapsidated at the site of replication (By similarity).Protein 3CD: Is involved in the viral replication complex and viral polypeptide maturation. It exhibits protease activity with a specificity and catalytic efficiency that is different from protease 3C. Protein 3CD lacks polymerase activity. The 3C domain in the context of protein 3CD may have an RNA binding activity (By similarity).Protease 3C: cleaves host DDX58/RIG-I and thus contributes to the inhibition of type I interferon production. Cleaves also host PABPC1 (By similarity).RNA-directed RNA polymerase: Replicates the viral genomic RNA on the surface of intracellular membranes. May form linear arrays of subunits that propagate along a strong head-to-tail interaction called interface-I. Covalently attaches UMP to a tyrosine of VPg, which is used to prime RNA synthesis. The positive stranded RNA genome is first replicated at virus induced membranous vesicles, creating a dsRNA genomic replication form. This dsRNA is then used as template to synthesize positive stranded RNA genomes. ss(+)RNA genomes are either translated, replicated or encapsidated (By similarity).</specific-function>
        <gene-name/>
        <locus/>
        <cellular-location>Virion</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>7.23</theoretical-pi>
        <molecular-weight>241975.505</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="12130">HRV-2</organism>
        <external-identifiers>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X02316</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>1617204</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P04936</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>POLG_HRV2</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.4.22.29</synonym>
          <synonym>P2A</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0019129|Genome polyprotein
MGAQVSRQNVGTHSTQNSVSNGSSLNYFNINYFKDAASNGASKLEFTQDPSKFTDPVKDV
LEKGIPTLQSPTVEACGYSDRIIQITRGDSTITSQDVANAIVAYGVWPHYLSSKDASAID
KPSQPDTSSNRFYTLRSVTWSSSSKGWWWKLPDALKDMGIFGENMFYHYLGRSGYTIHVQ
CNASKFHQGTLIVALIPEHQIASALHGNVNVGYNYTHPGETGREVKAETRLNPDLQPTEE
YWLNFDGTLLGNITIFPHQFINLRSNNSATIIAPYVNAVPMDSMRSHNNWSLVIIPICPL
ETSSAINTIPITISISPMCAEFSGARAKRQGLPVFITPGSGQFLTTDDFQSPCALPWYHP
TKEISIPGEVKNLVEICQVDSLVPINNTDTYINSENMYSVVLQSSINAPDKIFSIRTDVA
SQPLATTLIGEISSYFTHWTGSLRFSFMFCGTANTTVKLLLAYTPPGIAEPTTRKDAMLG
THVIWDVGLQSTISMVVPWISASHYRNTSPGRSTSGYITCWYQTRLVIPPQTPPTARLLC
FVSGCKDFCLRMARDTNLHLQSGAIAQNPVENYIDEVLNEVLVVPNINSSNPTTSNSAPA
LDAAETGHTSSVQPEDVIETRYVQTSQTRDEMSLESFLGRSGCIHESKLEVTLANYNKEN
FTVWAINLQEMAQIRRKFELFTYTRFDSEITLVPCISALSQDIGHITMQYMYVPPGAPVP
NSRDDYAWQSGTNASVFWQHGQAYPRFSLPFLSVASAYYMFYDGYDEQDQNYGTANTNNM
GSLCSRIVTEKHIHKVHIMTRIYHKAKHVKAWCPRPPRALEYTRAHRTNFKIEDRSIQTA
IVTRPIITTAGPSDMYVHVGNLIYRNLHLFNSEMHESILVSYSSDLIIYRTNTVGDDYIP
SCDCTQATYYCKHKNRYFPITVTSHDWYEIQESEYYPKHIQYNLLIGEGPCEPGDCGGKL
LCKHGVIGIVTAGGDNHVAFIDLRHFHCAEEQGVTDYIHMLGEAFGNGFVDSVKEHIHAI
NPVGNISKKIIKWMLRIISAMVIIIRNSSDPQTILATLTLIGCSGSPWRFLKEKFCKWTQ
LNYIHKESDSWLKKFTEACNAARGLEWIGNKISKFIEWMKSMLPQAQLKVKYLNELKKLN
LYEKQVESLRVADMKTQEKIKMEIDTLHDLSRKFLPLYASEAKRIKTLYIKCDNIIKQKK
RCEPVAIVIHGPPGAGKSITTNFLAKMITNDSDIYSLPPDPKYFDGYDQQSVVIMDDIMQ
NPAGDDMTLFCQMVSSVTFIPPMADLPDKGKAFDSRFVLCSTNHSLLTPPTITSLPAMNR
RFFLDLDIIVHDNFKDPQGKLNVAAAFRPCDVDNRIGNARCCPFVCGKAVSFKDRNSCNK
YSLAQVYNIMIEEDRRRRQVVDVMTAIFQGPIDMKNPPPPAITDLLQSVRTPEVIKYCEG
NRWIIPAECKIEKELNLANTIITIIANVIGMARIIYVIYKLFCTLQGPYSGEPKPKTKIP
ERRVVTQGPEEEFGMSLIKHNSCVITTENGKFTGLGVYDRFVVVPTHADPGKEIQVDGIT
TKVIDSYDLYNKNGIKLEITVLKLDRNEKFRDIRRYIPNNEDDYPNCNLALLANQPEPTI
INVGDVVSYGNILLSGNQTARMLKYSYPTKSGYCGGVLYKIGQVLGIHVGGNGRDGFSAM
LLRSYFTDVQGQITLSKKTSECNLPSIHTPCKTKLQPSVFYDVFPGSKEPAVLSEKDARL
QVDFNEALFSKYKGNTDCSINDHIRIASSHYAAQLITLDIDPKPITLEDSVFGTDGLEAL
DLNTSAGFPYIAMGVKKRDLINNKTKDISKLKEAIDKYGVDLPMVTFLKDELRKHEKVIK
GKTRVIEASSVNDTLLFRTTFGNLFSKFHLNPGIVTGSAVGCDPEVFWSKIPAMLDDKCI
MAFDYTNYDGSIHPIWFEALKQVLVDLSFNPTLIDRLCKSKHIFKNTYYEVEGGVPSGCS
GTSIFNTMINNIIIRTLVLDAYKNIDLDKLKIIAYGDDVIFSYIHELDMEAIAIEGVKYG
LTITPADKSNTFVKLDYSNVTFLKRGFKQDEKYNFLIHPTFPEDEIFESIRWTKKPSQMH
EHVLSLCHLMWHNGRDAYKKFVEKIRSVSAGRALYIPPYDLLLHEWYEKF</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0002965|6453 bp
ATGGGTGCACAGGTTTCAAGACAAAATGTTGGAACTCACTCCACGCAAAACTCTGTATCA
AATGGGTCTAGTTTAAATTATTTTAACATCAATTATTTCAAAGATGCTGCTTCAAATGGT
GCATCAAAACTGGAATTCACACAAGATCCTAGTAAATTTACTGACCCAGTTAAGGATGTT
TTGGAAAAGGGAATACCAACACTACAGTCCCCCACAGTGGAGGCTTGTGGATACTCTGAT
AGGATTATACAGATTACCAGAGGAGATTCAACCATAACCTCACAAGATGTGGCTAATGCT
ATCGTTGCGTATGGTGTTTGGCCACATTATCTATCCTCCAAGGATGCCTCTGCAATTGAT
AAACCCTCTCAACCAGATACATCTTCTAATAGATTTTATACTCTAAGGAGTGTGACCTGG
AGCAGTTCCTCAAAGGGTTGGTGGTGGAAACTACCTGATGCACTCAAGGACATGGGTATT
TTTGGTGAAAACATGTTTTATCATTACCTGGGTAGGAGTGGATACACAATACATGTGCAG
TGTAATGCTAGTAAATTTCACCAGGGTACACTAATTGTTGCTCTGATACCTGAGCATCAG
ATTGCAAGTGCCTTACATGGCAATGTGAATGTTGGTTACAACTACACACACCCAGGTGAA
ACAGGCAGGGAAGTTAAAGCTGAGACGAGATTGAATCCTGATCTACAACCTACTGAAGAG
TATTGGCTAAACTTTGATGGGACACTCCTTGGAAATATTACCATATTCCCTCATCAATTT
ATCAACTTGAGGAGTAATAATTCTGCCACAATAATTGCCCCTTATGTCAATGCAGTTCCT
ATGGATTCAATGCGGAGCCACAATAATTGGAGTTTGGTAATAATACCAATATGTCCCCTT
GAGACATCAAGTGCAATTAACACAATACCTATTACAATATCTATAAGCCCCATGTGTGCA
GAGTTTTCCGGCGCGCGTGCCAAGCGTCAAGGATTACCAGTTTTCATCACACCAGGTTCA
GGACAGTTTTTGACAACAGATGATTTCCAATCCCCATGTGCACTTCCCTGGTATCACCCA
ACTAAGGAAATTTCTATTCCAGGTGAGGTTAAAAATTTGGTTGAAATTTGTCAAGTAGAC
AGCCTAGTACCAATAAATAACACTGACACCTACATCAATAGTGAAAATATGTATTCTGTT
GTATTGCAATCATCAATTAATGCACCAGATAAGATCTTCTCTATTCGAACAGATGTTGCT
TCCCAACCTTTAGCTACTACTTTGATTGGTGAGATATCTAGCTATTTCACCCACTGGACA
GGGAGTCTCCGTTTCAGCTTCATGTTTTGTGGTACTGCCAACACTACTGTTAAGCTTTTG
TTGGCATACACACCACCTGGTATCGCAGAACCCACCACAAGAAAGGATGCAATGCTAGGC
ACTCATGTTATATGGGATGTGGGGTTGCAGTCTACAATATCAATGGTAGTGCCATGGATT
AGCGCTAGTCATTATAGAAACACATCACCAGGTAGATCTACATCTGGGTACATAACATGC
TGGTATCAGACTAGATTAGTCATTCCACCTCAGACCCCACCAACAGCTAGATTGTTATGT
TTTGTATCTGGGTGCAAAGACTTTTGCTTGCGCATGGCACGAGATACTAACCTACACCTG
CAAAGTGGTGCAATAGCACAGAACCCTGTTGAGAATTATATAGATGAAGTTCTTAATGAA
GTTTTAGTTGTCCCAAATATTAATAGTAGTAACCCCACAACATCAAATTCTGCCCCAGCA
TTAGATGCTGCAGAAACAGGGCACACTAGTAGTGTTCAACCAGAGGATGTCATTGAAACT
AGGTATGTGCAGACATCACAAACAAGAGATGAAATGAGTTTAGAGAGTTTTCTTGGCAGA
TCAGGATGCATACATGAATCTAAATTAGAGGTTACACTTGCAAATTATAACAAGGAGAAT
TTTACAGTGTGGGCTATTAATCTACAAGAAATGGCTCAAATTAGAAGGAAATTTGAATTG
TTCACCTATACTAGGTTTGATTCTGAAATAACCCTAGTTCCATGCATTTCCGCCCTTAGT
CAGGACATTGGACACATCACAATGCAATACATGTATGTTCCACCAGGTGCACCGGTGCCC
AATAGTAGGGACGATTATGCATGGCAGTCTGGCACTAATGCCTCTGTTTTCTGGCAACAT
GGACAGGCTTATCCAAGATTTTCCTTACCTTTCCTAAGTGTGGCATCTGCTTATTACATG
TTTTATGATGGGTATGATGAACAAGATCAAAACTATGGTACAGCAAACACAAATAACATG
GGGTCACTATGCTCTAGGATAGTAACAGAGAAACACATTCATAAAGTACATATAATGACA
AGAATCTATCACAAGGCTAAACATGTCAAGGCATGGTGTCCACGCCCACCCAGAGCGCTT
GAGTATACTCGTGCTCATCGCACTAATTTTAAAATTGAGGATAGGAGTATTCAGACAGCA
ATTGTGACCAGACCAATTATCACTACAGCTGGCCCCAGTGACATGTATGTTCATGTAGGT
AACCTTATTTATAGAAATCTTCATCTTTTCAACTCTGAGATGCATGAATCTATTTTGGTA
TCTTATTCATCAGATTTAATCATTTACCGAACAAACACTGTAGGTGATGATTACATTCCC
TCTTGTGATTGTACCCAAGCTACTTATTATTGCAAACATAAAAATAGATACTTCCCAATT
ACAGTTACAAGCCATGACTGGTATGAAATACAGGAAAGTGAGTACTATCCCAAACACATA
CAGTACAATTTGTTGATTGGTGAGGGCCCTTGTGAACCAGGTGACTGTGGTGGAAAGTTG
CTATGCAAACATGGTGTCATAGGTATAGTAACAGCTGGTGGTGATAATCATGTGGCTTTT
ATTGACCTTAGACACTTCCATTGTGCTGAAGAACAAGGGGTTACAGATTATATACATATG
CTAGGAGAAGCATTTGGAAATGGATTTGTGGATAGTGTAAAAGAACATATACATGCCATA
AACCCAGTAGGAAATATCAGCAAGAAAATTATTAAATGGATGTTGAGAATAATATCAGCA
ATGGTCATAATAATTAGAAACTCTTCTGACCCCCAAACTATATTAGCAACACTCACACTG
ATTGGGTGTTCTGGATCACCCTGGAGATTTTTAAAGGAAAAATTCTGTAAATGGACACAG
CTTAATTATATACACAAAGAATCAGATTCATGGTTAAAGAAATTTACTGAAGCATGCAAT
GCAGCTAGAGGGCTTGAATGGATAGGGAATAAGATATCTAAATTTATTGAATGGATGAAG
TCGATGCTCCCGCAAGCTCAATTGAAGGTTAAGTACTTAAACGAGCTTAAAAAACTCAAC
CTATACGAAAAGCAAGTTGAGAGCTTGCGGGTGGCTGACATGAAAACACAAGAAAAAATT
AAAATGGAAATAGACACTTTACATGATTTGTCACGTAAATTTCTACCTTTGTATGCAAGT
GAGGCAAAAAGGATAAAAACCCTATACATTAAATGTGATAATATCATCAAGCAGAAGAAA
AGATGTGAACCAGTAGCTATAGTTATTCATGGACCACCTGGTGCTGGCAAATCTATAACA
ACAAATTTCCTGGCCAAAATGATAACTAATGATAGTGACATATACTCTCTACCTCCTGAT
CCAAAATATTTTGATGGTTATGACCAACAGAGTGTAGTAATAATGGATGACATTATGCAG
AATCCAGCCGGGGATGACATGACACTGTTCTGCCAAATGGTTTCTAGTGTTACATTTATA
CCACCAATGGCTGATCTACCAGATAAAGGCAAGGCTTTTGATTCTAGGTTTGTATTATGC
AGCACAAATCATTCCCTTCTAACACCCCCGACAATAACTTCACTACCTGCAATGAATAGA
AGATTTTTCCTAGATTTAGATATAATAGTACATGATAACTTCAAAGATCCACAGGGCAAA
CTTAATGTGGCAGCAGCGTTTCGACCATGTGATGTAGATAATAGAATAGGAAATGCACGT
TGTTGTCCATTTGTGTGTGGAAAAGCAGTTTCTTTCAAAGATCGTAACTCTTGCAACAAA
TACAGCCTTGCGCAGGTGTACAACATAATGATTGAAGAAGACAGACGGAGAAGACAAGTG
GTTGATGTCATGACAGCTATATTCCAAGGGCCAATTGATATGAAAAACCCACCACCACCT
GCTATTACTGACTTGCTCCAGTCTGTTAGAACCCCTGAAGTTATTAAGTATTGTGAGGGT
AATAGATGGATAATTCCAGCAGAATGCAAGATAGAAAAGGAGTTGAACTTGGCTAACACA
ATCATAACAATCATTGCAAATGTTATTGGTATGGCGAGAATAATATATGTTATTTACAAA
CTTTTTTGCACATTACAGGGACCATATTCAGGAGAACCAAAGCCCAAGACTAAAATCCCA
GAAAGGCGTGTAGTAACACAGGGACCAGAGGAGGAATTTGGGATGTCTTTAATTAAACAT
AACTCATGTGTTATTACAACAGAAAATGGGAAATTCACAGGTCTTGGAGTATACGACAGA
TTTGTGGTCGTACCAACACATGCAGATCCTGGAAAGGAAATTCAGGTTGATGGTATAACT
ACAAAAGTCATTGACTCATATGACCTATACAACAAGAATGGGATAAAGCTAGAAATAACA
GTACTTAAATTAGATAGAAATGAAAAATTTAGAGATATCAGGAGATATATACCTAACAAT
GAAGATGATTACCCCAATTGCAACTTAGCACTGCTAGCAAACCAGCCTGAACCAACTATA
ATCAATGTTGGAGATGTTGTATCCTATGGCAATATACTGCTCAGTGGCAACCAAACGGCT
AGAATGCTTAAATACAGTTACCCAACTAAATCTGGTTACTGTGGAGGTGTCTTATACAAA
ATTGGGCAAGTGCTTGGAATACATGTTGGGGGCAATGGTAGGGATGGTTTCTCAGCTATG
TTACTCAGATCCTATTTCACTGATGTTCAGGGCCAAATAACGTTATCAAAGAAGACCAGT
GAATGTAACCTACCCAGTATACACACCCCATGCAAAACCAAATTGCAGCCTAGTGTTTTC
TATGATGTATTCCCTGGTTCAAAAGAACCAGCTGTGTTGTCTGAAAAAGATGCCCGGTTA
CAAGTTGATTTCAATGAAGCACTATTTTCTAAATACAAAGGGAATACAGATTGCTCCATT
AATGACCACATAAGAATTGCATCATCACATTATGCAGCACAACTCATTACCTTAGATATT
GACCCAAAACCTATTACACTTGAGGACAGTGTCTTTGGCACTGATGGATTAGAGGCTCTT
GATTTGAACACTAGCGCAGGATTTCCATATATTGCAATGGGAGTTAAAAAGAGAGATTTA
ATAAACAACAAGACCAAGGATATAAGCAAACTTAAAGAAGCAATTGACAAATACGGAGTT
GACTTACCTATGGTCACCTTCTTGAAAGATGAACTCAGAAAGCATGAAAAGGTAATTAAA
GGTAAAACTAGAGTTATTGAAGCTAGTAGTGTGAATGATACCCTATTATTTAGAACAACT
TTTGGCAACCTCTTTTCAAAGTTCCACTTGAATCCTGGAATTGTTACTGGATCAGCAGTT
GGATGTGATCCAGAGGTGTTTTGGTCAAAAATACCAGCAATGTTGGATGATAAATGTATT
ATGGCTTTTGATTATACAAATTATGATGGTAGTATACACCCTATTTGGTTTGAAGCTCTT
AAACAGGTACTGGTAGATCTATCATTTAATCCAACATTAATAGATAGACTATGCAAGTCT
AAACACATCTTCAAAAATACATACTATGAAGTGGAGGGAGGTGTACCATCTGGGTGTTCA
GGTACTAGTATTTTTAACACTATGATCAATAATATTATCATAAGGACCTTAGTGTTAGAT
GCATACAAGAATATAGATCTAGATAAGCTTAAGATAATTGCCTATGGTGATGATGTCATA
TTCTCATACATACATGAACTGGACATGGAGGCTATAGCAATAGAGGGTGTTAAATATGGT
TTGACTATAACTCCTGCTGATAAATCTAACACATTTGTAAAATTAGACTATAGCAATGTT
ACTTTTTTAAAAAGAGGGTTTAAGCAAGATGAGAAGTATAACTTTCTAATACATCCAACT
TTCCCTGAAGATGAAATATTTGAATCCATCAGATGGACAAAGAAACCATCACAAATGCAT
GAACATGTGTTGTCTCTGTGTCACTTAATGTGGCACAATGGACGTGACGCATACAAAAAA
TTTGTGGAGAAGATACGCAGTGTAAGCGCTGGTCGTGCACTGTACATCCCTCCGTATGAT
TTGCTTTTGCATGAGTGGTATGAAAAATTTTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00680</identifier>
            <name>RdRP_1</name>
          </pfam>
          <pfam>
            <identifier>PF08727</identifier>
            <name>P3A</name>
          </pfam>
          <pfam>
            <identifier>PF00548</identifier>
            <name>Peptidase_C3</name>
          </pfam>
          <pfam>
            <identifier>PF02226</identifier>
            <name>Pico_P1A</name>
          </pfam>
          <pfam>
            <identifier>PF00947</identifier>
            <name>Pico_P2A</name>
          </pfam>
          <pfam>
            <identifier>PF01552</identifier>
            <name>Pico_P2B</name>
          </pfam>
          <pfam>
            <identifier>PF00073</identifier>
            <name>Rhv</name>
          </pfam>
          <pfam>
            <identifier>PF00910</identifier>
            <name>RNA_helicase</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>host cell cytoplasmic vesicle membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral to membrane of host cell</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>T=pseudo3 icosahedral viral capsid</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cysteine-type endopeptidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ion channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>RNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>RNA helicase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>RNA-directed RNA polymerase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>structural molecule activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>DNA replication</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>endocytosis involved in viral entry into host cell</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>induction by virus of host autophagy</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>pore formation by virus in membrane of host cell</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>pore-mediated entry of viral genome into host cell</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive stranded viral RNA replication</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein oligomerization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>RNA-protein covalent cross-linking</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>suppression by virus of host gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>suppression by virus of host mRNA export from nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>suppression by virus of host RIG-I activity by RIG-I proteolysis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>suppression by virus of host translation initiation factor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transcription, DNA-templated</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>viral RNA genome replication</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>virion attachment to host cell</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>